Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Actos Lawsuits Continue To Be Filed By Wright & Schulte LLC Contending Development of Bladder Cancer After Taking Type Two Diabetes Medication
  • USA - English


News provided by

Wright & Schulte LLC

Oct 18, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Actos Lawsuits Continue To Be Filed By Wright & Schulte LLC Contending Development of Bladder Cancer After Taking Type Two Diabetes Medication
Actos Lawsuits Continue To Be Filed By Wright & Schulte LLC Contending Development of Bladder Cancer After Taking Type Two Diabetes Medication

Wright & Schulte LLC offers FREE Actos lawsuit evaluations to those who have been diagnosed with Actos bladder cancer. Visit www.yourlegalhelp.com, or call 1-800-399-0795

Post this

Columbus, OH (PRWEB) October 18, 2014 -- Wright & Schulte LLC has filed an Actos lawsuit on behalf of a Nebraska man who allegedly developed bladder cancer after using Actos to treat Type II diabetes. The Actos lawsuit against Takeda Pharmaceuticals America, Inc., states that the Nebraska man was prescribed the medication by his physician in 2009 for long-term maintenance of his diabetes. In March 2011, the plaintiff was diagnosed with bladder cancer, according to the Actos complaint. The Actos claim contended that as a result of the plaintiff’s long-term use of Actos, he has suffered permanent and severe injuries and requires ongoing medical care and treatment. The complaint purports that Takeda should have known that using Actos on a daily basis for more than 12 months presents a significantly increased risk of illness and injuries, including bladder cancer. According to the lawsuit, the plaintiff would not have taken Actos had Takeda properly disclosed the risks associated with long-term use of the medication. The Actos lawsuit was filed in the Circuit Court of Cook County, Illinois.(Case No. 2014-L-006270)

The firm is currently representing numerous clients from around the country in Actos lawsuits. If you believe you have developed bladder cancer or other drug side-effects contact one of the attorneys at Wright & Schulte LLC by calling 1-800-399-0795 or visit http://www.yourlegalhelp.com for more information.

Actos, generically known as pioglitazone, was approved by the U.S. Food & Drug Administration (FDA) in 1999 to treat Type II diabetes. In June 2011, the FDA warned that patients taking Actos for more than one year may be at an increased risk of developing bladder cancer. The FDA issued the warning after reviewing a study in 2010 that was conducted in France and focused on 1.5 million diabetic patients who were followed from 2006 to 2009. The study found a statistically significant increase in the risk for bladder cancer in males who took pioglitazone compared to other patients exposed to other drugs that treat diabetes. As a result of the study’s findings, France suspended sales of medication containing pioglitazone and the FDA said that Germany recommended that new patients should not be started on pioglitazone. While Actos sales were not suspended in the United States, the FDA recommended to healthcare professionals that patients with active bladder cancer and those who had a history of bladder cancer should not use pioglitazone.
[fda.gov/drugs/drugsafety/ucm259150.htm, June 15, 2011] [ema.europa.eu/docs/en_GB/document_library/Press_release/2011/06/WC500107515.pdf, June 9,2011]

Court records indicate that Actos lawsuit flings are mounting in multidistrict litigation in the U.S. District Court for the Western District of Louisiana (In Re: Actos (Pioglitazone) Products Liability Litigation-MDL 2299). The 3,672 pending Actos complaints have been consolidated in the Louisiana federal court for pretrial proceedings under the supervision of U.S. District Judge Rebecca F. Doherty. All of the Actos lawsuits were filed on behalf of individuals who allege one or more serious side effects, including bladder cancer, heart failure and liver problems as a result of using Actos.
[jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-August-15-2014.pdf, August 15, 2014]

Court records further indicate that the first trial for an Actos bladder cancer lawsuit filed under MDL 2299 was held in April in the Western Louisiana federal court. The jury ordered Takeda Pharmaceuticals USA Inc. and Eli Lilly & Co. to pay a combined $9 billion in punitive damages to a New York man who alleged in his lawsuit that he developed bladder cancer as a result of taking Actos since 2006. (12-cv-00064) The jury found that the companies did not disclose the bladder cancer risk associated with using Actos. Bloomberg reported that the companies appealed the $9 billion verdict. In August, Judge Doherty, who presided over the jury trial, upheld the $9 billion verdict and said in her 101-page opinion that the jury “properly considered evidence” that showed officials from both companies knew about Actos’ link to bladder cancer and did not disclose that information to doctors and their patients. According to data compiled by Bloomberg, this is the second-largest jury verdict in the U.S. in 2014.
[bloomberg.com/news/2014-08-28/takeda-lilly-lose-bid-to-get-9-billion-actos-award-thrown-out.html, August 28, 2014.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Actos lawsuit case evaluations and other harmful drug lawsuit evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Richard Schulte, Wright & Schulte LLC, http://yourlegalhelp.com/, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.